Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech), making it one of the largest healthcare companies globally. Investors research JNJ for its established market position, dividend history, and exposure to aging demographics and chronic disease treatment.
Get a full AI research report on JNJ
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Johnson & Johnson do?
JNJ generates revenue through two primary segments: Innovative Medicine, which develops and sells prescription pharmaceuticals across oncology, immunology, neuroscience, and infectious disease; and MedTech, which manufactures surgical instruments, orthopedic devices, cardiovascular products, and vision-care solutions sold to hospitals, physicians, and healthcare systems worldwide. The company operates an integrated model spanning research, manufacturing, and distribution, with products reaching end-users through wholesalers, retailers, and direct healthcare provider relationships. This dual-segment structure provides revenue diversification across both high-margin pharmaceuticals and medical device categories.
Bull case
- ✓Strong profitability metrics with a 21.5% net margin and 29.2% operating margin, indicating efficient cost management and pricing power in its therapeutic categories.
- ✓Solid return on equity of 25.7% and return on assets of 8.6% demonstrate effective capital deployment relative to peers in the pharmaceutical sector.
- ✓Dividend yield of 2.05% with a 60.8% payout ratio suggests sustainable shareholder returns with room for reinvestment in R&D and acquisitions.
- ✓Diversified revenue streams across two distinct business segments reduce dependence on any single therapeutic area or product category.
- ✓Gross margin of 68.1% reflects strong pricing and product mix, particularly in higher-margin pharmaceutical products.
Bear case
- ✗Trailing P/E ratio of 30.2 is elevated relative to historical averages and many healthcare peers, potentially limiting upside if earnings growth slows.
- ✗High debt-to-equity ratio of 57.7% indicates significant leverage, which may constrain financial flexibility during downturns or for major acquisitions.
- ✗Quick ratio of 0.725 is below 1.0, suggesting potential near-term liquidity constraints if current liabilities come due without asset sales.
- ✗Forward P/E of 21.1 and PEG ratio of 4.32 imply the market is pricing in meaningful earnings growth; any miss could result in valuation compression.
- ✗Patent expirations on key drugs and generic competition in the pharmaceutical segment pose ongoing revenue headwinds requiring continuous innovation.
JNJ valuation & financial health
Johnson & Johnson trades at a trailing P/E of 30.2 and forward P/E of 21.1, reflecting a premium valuation typical of large-cap healthcare leaders with stable cash flows. The company's gross margin of 68.1% and operating margin of 29.2% demonstrate strong pricing and operational efficiency, while net margin of 21.5% shows solid bottom-line profitability. However, the debt-to-equity ratio of 57.7% is notably high, and the quick ratio of 0.725 suggests reliance on inventory conversion and operating cash flow to meet short-term obligations. ROE of 25.7% and ROA of 8.6% indicate effective capital utilization, though the elevated leverage means much of the equity return is amplified by debt. The dividend payout ratio of 60.8% leaves room for earnings growth reinvestment while maintaining shareholder distributions.
The bottom line
Johnson & Johnson presents the profile of a mature, profitable healthcare company with strong margins and diversified revenue streams, but investors face key considerations around valuation and leverage. The forward P/E of 21.1 is more reasonable than the trailing multiple, suggesting the market expects earnings growth; however, the high debt load and tight quick ratio warrant monitoring of refinancing risk and working capital management. Factors to weigh include the company's ability to sustain innovation pipelines amid patent cliffs, the sustainability of its dividend given leverage levels, and whether current valuations leave adequate margin of safety for long-term investors. What to monitor: earnings growth rates relative to the forward P/E assumption, debt reduction progress, and pipeline advancement in key therapeutic areas.
Frequently asked questions
What does Johnson & Johnson do?
JNJ operates two main business segments: Innovative Medicine (prescription pharmaceuticals in oncology, immunology, neuroscience, and infectious disease) and MedTech (surgical instruments, orthopedic devices, cardiovascular products, and vision care). The company researches, manufactures, and distributes these products globally to hospitals, physicians, wholesalers, and retailers.
Is Johnson & Johnson profitable?
Yes, JNJ is highly profitable with a net margin of 21.5%, operating margin of 29.2%, and gross margin of 68.1%. The company generated strong returns on equity (25.7%) and assets (8.6%), indicating efficient use of capital.
Is JNJ overvalued at current prices?
JNJ trades at a trailing P/E of 30.2, which is elevated, but the forward P/E of 21.1 reflects market expectations for earnings growth. Whether the valuation is justified depends on whether the company can sustain that growth rate; investors should compare these multiples to historical averages and peer benchmarks.
Does Johnson & Johnson pay a dividend?
Yes, JNJ has a dividend yield of 2.05% with a payout ratio of 60.8%, indicating a sustainable and well-covered dividend with room for growth. The company is known for consistent dividend increases over decades.
What are the main risks for JNJ investors?
Key risks include patent expirations on major drugs, generic competition, a high debt-to-equity ratio of 57.7%, a quick ratio below 1.0 suggesting liquidity constraints, and elevated valuation multiples that leave limited margin for error if earnings disappoint.
How does JNJ compare to other healthcare stocks?
JNJ's 21.5% net margin and 25.7% ROE are strong relative to many healthcare peers, but its 57.7% debt-to-equity ratio is higher than some competitors. The forward P/E of 21.1 is in line with large-cap pharma, though investors should compare growth rates and pipeline strength across the sector.
Research JNJ with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.